

H9

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, PO Box 2327, Arlington, VA 22202 on December 2, 2002.

Patent Application  
Docket No. GJE-88  
Serial No. 10/070,568

David Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : You-Min Feng, You-Shang Zhang  
 Serial No. : 10/070,568  
 Conf. No. : 7193  
 Filed : March 8, 2002  
 For : Monomeric Analogues of Human Insulin

U.S. Patent and Trademark Office  
 BOX SEQUENCE, P.O. Box 2327  
 Arlington, VA 22202

TRANSMITTAL LETTER

Sir:

The Applicants have received a second Notification of Defective Response Under 35 U.S.C. 371 from the United States Designated/Elected Office (DO/EO/US), dated November 18, 2002, in the above-referenced patent application. The Notification requests that the applicants comply with Sequence Disclosure Requirements under 37 CFR §1.821.

Transmitted herewith is a Submission of Sequence Listing Under 37 CFR 1.821, Submission of Sequence Listing on paper and in computer readable format (disk), an Submission of Sequence Listing under 37 CFR 1.821-1.825, Amendment under 37 CFR §1.825(a) through (c), and a copy of the Notification of Defective Response.

The Commissioner is hereby authorized to charge any additional fees that may be required to  
Deposit Account No. 19-0065.

Respectfully submitted,



David R. Saliwanchik  
Patent Attorney  
Registration No. 31,794  
Phone No.: 352-375-8100  
Address : 2421 N.W. 41st Street  
Suite A-1  
Gainesville, FL 32606

DRS/la

Attachments: Submission of Sequence Listing under 37 CFR § 1.821;  
Sequence Listing on paper and computer readable format (disk);  
Copy of Notification of Defect; and  
Amendment under 37 CFR §1.825(a) through (c)